Inve US ▾
HNHNGE

Hinge Health (HNGE) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 4, 2026

Source: earnings call transcript

Executive summary

Hinge Health Q2 FY26 — Strong Growth, Margin Expansion, and Strategic GI Acquisition

Hinge Health delivered a robust second quarter, marked by significant revenue growth, substantial margin expansion, and strong free cash flow generation. The company's multi-product strategy is gaining traction with the successful launch of its Migraine Care Program and the strategic acquisition of Cylinder Health to enter the GI market. Management remains confident in its platform's ability to drive clinical outcomes, growth, and cash flow, while also returning capital to shareholders.

Highlights

5
  • Revenue reached $213 million, representing 53% year-over-year growth, exceeding guidance of $200M-$202M.

  • Operating income more than doubled to $62 million, with operating margin expanding to 29% from 19% YoY.

  • Free cash flow tripled to $100 million, achieving a 47% free cash flow margin, up from 23% YoY.

  • LTM calculated billings grew 52% year-over-year to $862 million, driven by stronger-than-expected yield improvements.

  • Acquired Cylinder Health for $105 million in cash, accelerating entry into the gastrointestinal health market.

Guidance & targets

CategoryTargetConfidence
Q3 FY26 Revenue
$223M-$225M
high materiality
High
Q3 FY26 Income from Operations
$61M-$63M
high materiality
High
Full Year FY26 Revenue
$856M-$860M
high materiality
High
Full Year FY26 Income from Operations
$236M-$244M
high materiality
High
Full Year FY26 Yield
around 4.45%
high materiality
High
Full Year FY26 Diluted Shares Outstanding
85M-87M shares
medium materiality
Medium
Share Repurchase Authorization
$300M
high materiality
High
Cylinder Health Revenue Contribution
$7M-$8M
medium materiality
High
Cylinder Health Revenue Contribution
meaningfully more
medium materiality
Medium
Migraine Yield Improvement
10-20 bps
medium materiality
High

HNGE operating KPIs by quarter

HNGE operating KPIs stated on its earnings calls, by fiscal quarter
KPI Mar 2026 Q1 FY26This call Jun 2026 Q2 FY26Change vs prior quarter
Provider locations Hinge Select
4,100 We ended Q1 with 4,100 provider locations, and we're also thrilled to share that we recently expanded Hinge Select access through 1 of our national PBM partners and 3 of the 5 largest national health plans by self-insured lives. Source: earnings call transcript
5,000+ We've also expanded our provider network spanning over 5,000 locations now. Source: earnings call transcript
—

Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.

Product announcements

ProductTypeDetails
Migraine Care Programlaunch
Gastrointestinal (GI) Care Programlaunch
HingeSelect with surgerylaunch

Deals & partnerships

Cylinder Health Acquisition of a gastrointestinal health company to accelerate entry into the GI market. $105M in cash

Cylinder Health has nearly 100 clients across 2 million lives and has treated 150,000 people. They have partnerships with two of the three largest PBMs and three of the top five national health plans. The acquisition provides a strong foundation and an 18-24 month head start in the digestive health sector. 52 of Cylinder's clients are also Hinge Health clients. Nearly all Cylinder employees, including leadership, are expected to transition.

What to watch in Q3 FY26

Cylinder Health Integration and Revenue Contribution

Q3 FY26, FY27, FY28
Current Acquisition expected to close in Q3 FY26, with $7M-$8M revenue contribution for remaining 4 months of FY26.
Target Meaningful revenue contribution in FY27 and beyond, with broader rollout targeted for 2027.

Why it matters

The successful integration and scaling of Cylinder Health's GI offering is critical for Hinge Health's multi-product strategy and long-term TAM expansion.

We expect Cylinder to contribute approximately $7 million to $8 million in revenue for the remaining approximate four months of 2026 and meaningfully more in 2027 onwards as we integrate and scale the offering.

Find out whether HNGE delivers this. Inve re-checks your case every morning.

Q&A highlights

How replicable is Hinge Health's core care model for GI, considering potential needs for more live/in-person sessions, and what aspects of the core model can be applied to GI and Cylinder?

The GI care model will be tech and AI-driven at its core, similar to MSK and Migraine, delivering personalized nutrition guidance and intelligent identification of triggers. It will pair technology with improved access to GI specialists for human support when needed. The acquisition of Cylinder Health provides an 18-24 month head start, as Cylinder's functions and go-to-market motion are analogous to Hinge Health's, with shared partners and customers.

“So similar to MSK and Migraine programs, our GI care program will first be tech and AI-driven at its core. So we're going to deliver best-in-class GI care through an AI-led experience, personalized nutrition guidance, easy tracking of what members eat, how their bodies respond, intelligent identification of triggers behind their digestive issues to get clear personalized plan instead of the fragmented care that's typical today.”

asked by Ryan MacDonald · answered by Daniel Perez

2 min read 6 chapters

Detailed narrative

Q2 Financial Outperformance and Operating Leverage

Hinge Health reported a strong Q2 FY26, with revenue of $213 million, significantly exceeding guidance, driven by better-than-expected billings and durable yield improvements. The company demonstrated substantial operating leverage, with operating income more than doubling to $62 million and operating margin expanding by 1,000 basis points year-over-year to 29%.

Free cash flow also saw a significant increase to $100 million, representing a 47% margin, highlighting the business's strong cash generation capabilities.

Strategic Product Expansion: Migraine and GI Health

Building on its leadership in musculoskeletal (MSK) care, Hinge Health is expanding its platform to address additional conditions. The Migraine Care Program, launched last quarter, has seen rapid adoption with over 450 clients covering 5 million lives. The company announced its entry into gastrointestinal (GI) health through the acquisition of Cylinder Health for $105 million.

This acquisition provides a strong foundation in a market affecting 1 in 4 U.S. adults and is highly comorbid with existing conditions, leveraging Hinge Health's established go-to-market motion.

Commercial Momentum and Multi-Product Strategy

The company's commercial pipeline remains strong, with active pipeline ahead of last year and win rates at an all-time high. Strategic investments in the SMB segment are paying off, with lives grown over 100% year-over-year in H1 FY26, including a default solution selection by a large national health plan.

The multi-product strategy, including HingeSelect with surgery and the new Migraine and GI offerings, is driving deeper client relationships and expanding the company's impact across a wider array of outcomes and cost savings.

Yield Improvements and Growth Drivers

Yield, a key driver of revenue, is expected to reach approximately 4.45% for FY26, up from 4.3% previously, primarily due to clinically targeted enrollment campaigns, member-to-member referrals, and member renewals. These initiatives are delivering consistent results and are broad-based across existing and new clients.

The company anticipates further yield expansion from new products like Migraine and GI, which offer additional opportunities to engage members and expand the addressable market.

Capital Allocation and Shareholder Returns

Hinge Health ended the quarter with $476 million in cash and equivalents. The company repurchased 480,000 shares for $26 million in Q2 and announced a new $300 million share repurchase authorization. This reflects a balanced capital allocation strategy focused on organic product investments, strategic tuck-in acquisitions like Cylinder Health, and returning capital to shareholders, all supported by robust free cash flow generation.

Clinical Evidence and Outcomes

Hinge Health continues to demonstrate clinical rigor, publishing its 23rd clinical study on its fall prevention program. The study, published in the Journal of Comparative Effectiveness Research, showed a 37% reduction in falls and 57% lower odds of an emergency room visit for adults 65 and older using the program.

This commitment to evidence-based outcomes reinforces client satisfaction and retention, particularly in the Medicare Advantage market.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.